Chronic myeloid leukaemia trials in United States

In United States 100 Also abroad 171

100 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
Where
Cleveland, Duarte
Age
18 years and over
People
15
Run by
City of Hope Medical Center
See details and how to joinNCT06543381
Phase 1/2Taking people
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Where
Augusta, Birmingham, Eugene, Fort Myers, Gilbert, Houston, Lone Tree, Nashville, New York, Ocala, Orange, Philadelphia, Portland, Salt Lake City, Seattle, St. Petersburg, West Palm Beach, Winston-Salem
Age
18 years to 64 years
People
330 worldwide
Run by
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
See details and how to joinNCT06163430 · EU 2023-507677-18-00
Phase 2Taking people
Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis
Where
Boston
Age
18 years and over
People
120
Run by
Massachusetts General Hospital
See details and how to joinNCT06691217
Phase 2Taking people
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Where
Houston
Age
18 years and over
People
40
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT07269470
Phase 1/2Taking people
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Where
Houston
Age
18 years and over
People
66
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT07128381
Phase 2Taking people
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Where
Duarte
Age
18 years and over
People
35
Run by
City of Hope Medical Center
See details and how to joinNCT07582172
No phaseTaking people
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Where
Houston
People
3,000
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT00816114
No phaseTaking people
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Where
Atlanta, Birmingham, Chapel Hill, Charleston, Dallas, Evanston, Glenn Dale, Kansas City, La Jolla, Lincoln, New Orleans, New York, Normal, Oklahoma City, Omaha, Pittsburgh, Rochester, San Diego, Scottsdale, St Louis, Tampa, Tucson, Walnut Creek, Warwick
Age
18 years and over
People
750 worldwide
Run by
Blueprint Medicines Corporation
See details and how to joinNCT07143669
Phase 1Taking people
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Where
Houston
Age
18 years and over
People
38
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT03896269
Phase 1/2Taking people
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Where
Houston
Age
18 years and over
People
97
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT04140487
Phase 2/3Taking people
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Where
Atlanta, Boston, Buffalo, Charleston, Columbus, Dallas, Durham, Hackensack, Houston, Los Angeles, Miami, Milwaukee, Mineola, Nashville, New Haven, New York, Orange, Portland, Salem, Seattle, The Bronx
Age
18 years and over
People
316 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00
Early phase 1Taking people
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Where
Baltimore
Age
18 years and over
People
8
Run by
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
See details and how to joinNCT06398457
Phase 2Taking people
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib
Where
Houston
Age
18 years and over
People
50
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT06817720
Phase 2Taking people
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Where
Eau Claire, La Crosse, Mankato, Rochester
Age
18 years and over
People
80
Run by
Mayo Clinic
See details and how to joinNCT03418038
Phase 1Taking people
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
Where
Houston
Age
18 years and over
People
30
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT06401603
Phase 1Taking people
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Where
Houston
Age
1 year and over
People
58
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT03630991
Phase 1Taking people
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Where
Seattle
Age
18 years and over
People
120
Run by
Fred Hutchinson Cancer Center
See details and how to joinNCT04375631
Phase 2Taking people
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Where
Houston
Age
18 years and over
People
50
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT01746836
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Atlanta, Birmingham, Boston, Charleston, Chicago, Cleveland, Duarte, Hialeah, Houston, Los Angeles, New York, Phoenix, Salt Lake City, Stanford
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 3Taking people
Study of Olverembatinib (HQP1351) in Patients With CML-CP
Where
Albuquerque, Amarillo, Anchorage, Augusta, Austin, Baltimore, Birmingham, Chattanooga, Chicago, Cleveland, Decatur, Detroit, Duarte, Edmonds, Goodyear, Greenville, Hackensack, Houston, Indianapolis, Irvine, Issaquah, La Jolla, Las Vegas, Lexington, Lincoln, Long Beach, Los Angeles, Louisville, Mayfield Heights, Morristown, Morrisville, Nashville, New Brunswick, Newnan, Philadelphia, Pittsburgh, Portland, Reno, Rochester, Sacramento, Seattle, Shirley, St Louis, Stony Brook, Upland, Virginia Beach, Wichita
Age
18 years and over
People
333 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06423911 · EU 2024-511495-32-00
Phase 2Taking people
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Where
Houston
Age
18 years and over
People
50
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT03683433
Phase 2Not yet taking people in United States
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
Where
Seattle
People
52
Run by
Fred Hutchinson Cancer Center
See details and how to joinNCT07819396
Phase 2Taking people
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Where
Houston, Miami
Age
18 years and over
People
15
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT06566742
Phase 2Taking people
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Where
Baltimore, Cleveland, Houston
Age
12 years and over
People
63
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT03383575
Phase 1/2Taking people
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Where
Birmingham, Boston, Chapel Hill, Dallas, Duarte, Goodyear, Greenville, Houston, Jacksonville, Lake Success, Morristown, Newnan, New Orleans, New York, Phoenix, Rochester, Scottsdale, Tampa, Zion
Age
12 years and over
People
160 worldwide
Run by
Sellas Life Sciences Group
See details and how to joinNCT04588922